A new study examined the toxicity and efficacy of intravenous AEZS-108, a conjugate of a peptide targeting the luteinizing-hormone-releasing hormone (LHRH) receptor and doxorubicin, in patients with castration-resistant and taxane-resistant prostate cancer. The maximum tolerated dose was 210 mg/m2 and the dose-limiting adverse event was persistent neutropenia. Nine of 10 patients evaluable by RECIST achieved stable disease. Three patients had a PSA response and 10 patients had PSA stable disease.
References
Liu, S. V. et al. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. Clin. Cancer Res. 10.1158/1078-0432.CCR-14-0489
Rights and permissions
About this article
Cite this article
LHRH-receptor-targeted doxorubicin shows promise. Nat Rev Urol 11, 660 (2014). https://doi.org/10.1038/nrurol.2014.295
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.295